北京天坛医院品牌怎么样 申请店铺

我要投票 北京天坛医院在男科医院行业中的票数:177 更新时间:2025-04-21
北京天坛医院是哪个国家的品牌?「北京天坛医院」是首都医科大学附属北京天坛医院旗下著名品牌。该品牌发源于北京市,由创始人王院长在1956年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力北京天坛医院品牌出海!通过在本页面挂载北京天坛医院品牌的产品链接和联系邮箱,可以提高北京天坛医院产品曝光!跨境电商爆单神器,目前只要100元/年哦~

北京天坛医院怎么样


首都医科大学附属北京天坛医院始建于1956年8月23日,是一所以神经外科为先导,神经科学为特色,集医、教、研、防为一体的三级甲等综合性医院。是世界三大神经外科研究中心之一、亚洲的神经外科临床、科研、教学基地。医院总占地面积83900.56平方米,建筑面积 92898.56平方米,编制床位950张,临床、医技科室45个,全院职工总数2787人。年门急诊量约140余万人次,年住院病人约3万人次,年手术量2万余例次。

北京市神经外科研究所、国家神经系统疾病临床医学研究中心、北京市伽玛刀治疗研究中心、北京市脑血管病抢救治疗中心、国家脑血管病创新药物临床评价技术平台、WHO在中国的神经科学培训合作中心、北京脑重大疾病研究院脑卒中研究所、北京脑重大疾病研究院脑肿瘤研究所、北京神外学院、首都医科大学第五临床医学院、全国脑血管病防治办公室、北京市脑血管病临床研究中心、北京市脑血管病防治指导办公室、中国卒中培训项目以及《中华神经外科杂志》、《中国卒中杂志》等一批机构设在我院。

功能神经外科和清华大学联合被授予神经调控工程中心称号;我院的脑血管病中心是北京市脑血管病临床研究中心和国家“十二五”重大新药创制脑血管病临床评价的依托平台;赵继宗教授获得了“2012年Walter E. Dandy神经外科学会荣誉奖”;戴建平教授入选美国科学院2012年新一批外籍院士,成为继巴德年、陈竺、韩启德之后又一来自中国的该院外籍院士;王拥军副院长获得 2012年首都危险疾病科技成果推广专项和北京市科技惠民奖,主编了2012 年卫生部颁布的《缺血性脑卒中诊断和诊疗质量控制》。

2013年12月19日赵继宗教授当选为中国科学院院士。

我院作为北京市医改第三批试点医院,实施了医药分开试点工作,深入推动了医院管理体制机制变革。开展电子病历、临床路径、DRGs付费、缩短平均住院日、抗菌药物监管治理、加强危急值的管理、处方点评、加强床位管理、优质护理服务等方面的工作。

我院承担了西藏自治区、新疆维吾尔自治区和内蒙古自治区所辖5所医院,以及东城区和丰台区的五所医院的对口支援任务。

医院全体职工在医院党委和领导班子的带领下,发扬王忠诚院士开拓创新、团结协作、严谨求实、艰苦奋斗、病人优先的精神,推动我国神经科学事业向更高水平发展。以“全心全意为病人服务”为宗旨,推进服务质量和医疗质量管理为核心的医疗管理体系;提升学科和人才队伍建设水平,培养更多热爱医院、有才华的专业和管理年轻人才;继续实施绩效管理,创建以绩效考核为核心的人力资源管理体系;完善各项管理监督机制,创建以成本核算为核心的后勤管理体系;推进新院迁建工作尽早进入建设阶段,推动天坛医院实现新的历史跨越,让天坛品牌永葆辉煌。


Beijing Tiantan Hospital, affiliated to Capital Medical University, was founded on August 23, 1956. It is a third-class comprehensive hospital with neurosurgery as the guide and neuroscience as the feature, integrating medicine, teaching, research and prevention. It is one of the three neurosurgery research centers in the world and the clinical, scientific and teaching base of neurosurgery in Asia. The hospital covers an area of 83900.56 square meters, with a building area of 92898.56 square meters. It has 950 beds, 45 clinical and medical technology departments, and 2787 employees. The annual outpatient and emergency treatment volume is about 1.4 million person times, the annual inpatient volume is about 30000 person times, and the annual operation volume is more than 20000. Beijing neurosurgery Research Institute, National Clinical Medicine Research Center for nervous system diseases, Beijing gamma knife treatment research center, Beijing cerebrovascular disease rescue and treatment center, national cerebrovascular disease innovative drug clinical evaluation technology platform, who China neuroscience training cooperation center, stroke research institute of Beijing Institute of major brain diseases, Beijing major brain disease research center The Institute of brain tumor research, Beijing Shenwai college, the fifth Clinical Medical College of Capital Medical University, the National Office of cerebrovascular disease prevention and control, Beijing clinical research center of cerebrovascular disease, Beijing cerebrovascular disease prevention and control guidance office, China stroke training program, China Journal of Neurosurgery, China stroke journal and other institutions are located in our hospital. Functional neurosurgery and Tsinghua University were jointly awarded the title of neuroregulation Engineering Center; the cerebrovascular disease center of our hospital is the supporting platform for clinical evaluation of Beijing cerebrovascular disease clinical research center and national "12th Five Year Plan" major new drug creation cerebrovascular disease; Professor Zhao Jizong won the "2012 Walter E. dandy neurosurgery society honorary Award"; Professor Dai Jianping was selected into American Science In 2012, a new group of foreign academicians of the Academy became another foreign academician from China after badian, Chen Zhu and Han Qide. Wang Yongjun, vice president of the Academy, won the special promotion project of scientific and technological achievements of dangerous diseases in the capital in 2012 and the Beijing Science and Technology Award for the benefit of the people, and edited the diagnosis and treatment quality control of ischemic stroke issued by the Ministry of health in 2012. On December 19, 2013, Professor Zhao Jizong was elected as an academician of the Chinese Academy of Sciences. As the third batch of pilot hospitals of Beijing medical reform, our hospital has carried out the pilot work of separating medicine and further promoted the reform of hospital management system and mechanism. Carry out the work of electronic medical record, clinical pathway, DRGs payment, shortening the average length of stay, antimicrobial drug supervision and management, strengthening the management of critical value, prescription review, strengthening bed management, quality nursing services, etc. Our hospital has undertaken the counterpart support tasks of five hospitals under the jurisdiction of Tibet Autonomous Region, Xinjiang Uygur Autonomous Region and Inner Mongolia Autonomous Region, as well as five hospitals in Dongcheng District and Fengtai District. Under the leadership of the hospital Party committee and the leading group, all staff of the hospital carry forward the spirit of Academician Wang Zhongli's pioneering innovation, unity and cooperation, rigorous and realistic, hard work and patient priority, and promote the development of neuroscience in China to a higher level. With the purpose of "serving patients wholeheartedly", promote the medical management system with service quality and medical quality management as the core; improve the level of discipline and talent team construction, cultivate more professional and management young talents who love hospitals and have talent; continue to implement performance management, create a human resource management system with performance assessment as the core; improve various management and supervision mechanisms To establish a logistics management system with cost accounting as the core; to promote the relocation of the new hospital to enter the construction stage as early as possible, to promote the Tiantan Hospital to achieve a new historical leap, so that the brand of Tiantan will remain brilliant forever.

本文链接: https://brand.waitui.com/5984c1b65.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

第一资本获批收购Discover

美国联邦储备委员会和货币监理署近日宣布,已批准第一资本金融公司(Capital One)收购发现金融服务公司(Discover Financial Services)的申请。这一交易还将使第一资本间接收购Discover Bank。此前,第一资本于2024年2月20日首次宣布与Discover达成一项最终协议。根据该协议,第一资本将通过全股票交易收购Discover,交易价值为353亿美元。(界面新闻)

52分钟前

中信证券:自主科技、受益欧洲资本开支扩张的板块等配置上将占优

中信证券研报表示,贸易战僵持阶段,超预期的刺激和基于妥协的贸易协议都很难发生;僵持阶段比的是两国的经济韧性,中国的政策选项更多、空间更大、能耗更久,对美国而言,7月前大规模的国债到期可能会是特朗普关税政策的第一个动摇点;A股也是中国贸易战中提振信心的关键环节,应充分相信国家维护资本市场稳定的决心,港股可能是阶段性的薄弱环节,但也要看到内地资金依旧整体明显低配港股。配置上,从规避不确定性的角度,自主科技、受益欧洲资本开支扩张的板块、纯内需必选消费、稳定红利以及不依赖短期业绩的题材料将占优。(证券时报)

52分钟前

盛和资源:MP公司暂停向中国出口稀土精矿不会对公司生产经营产生重大影响

4月20日,盛和资源(600392)发布公告称,网上出现“美国稀土生产商MP Materials(简称“MP公司”)宣布因关税停止向中国出口稀土精矿”的相关报道,公司就相关情况说明如下:2024年1月,MP公司与公司控股子公司盛和资源(新加坡)国际贸易有限公司再次续签了新的包销协议,盛和资源(新加坡)国际贸易有限公司为MP公司在中国的独家经销商;协议期限2年,到期后可延长1年;包销产品除稀土精矿外,还有其他稀土产品。截至目前,双方签署的包销协议尚在有效期内。目前因加征关税,MP公司暂时停止向中国出口稀土精矿。公司已构建了多元化的稀土原料供应渠道,四川矿、独居石以及其他国家进口矿可以作为替代供应。MP公司暂停向中国出口稀土精矿不会对公司生产经营产生重大影响。(新浪财经)

52分钟前

华为将发布兆瓦级超充产品

华为将于4月22日召开2025华为智能电动&智能充电网络战略与新品发布会。据了解,发布会上,华为将发布兆瓦级超充产品。根据华为此前的预告,该兆瓦级充电产品最大充电电流2400安培,最大功率1.5兆瓦,每分钟能补给20度电,15分钟可充满一辆电动重卡(约300度电池容量)。(财联社)

52分钟前

马来西亚航空考虑购买中国商飞飞机

据俄罗斯卫星社网站4月20日报道,马来西亚航空正在考虑购买中国国产飞机,中国商飞的三款商用机型C909、C919和C929都在评估范围内。马来西亚航空集团相关负责人18日对媒体表示,公司在制定未来几年的机队扩张计划,正密切评估购买中国商飞公司的飞机,双方团队已有过多轮沟通。报道称,被问及具体对C909、C919和C929中的哪款机型更感兴趣,该负责人表示,所有都在考虑之中,“我们在梳邦国际机场的运营就很适合商飞的小机型”。(界面新闻)

52分钟前

本页详细列出关于郑州颐和医院的品牌信息,含品牌所属公司介绍,郑州颐和医院所处行业的品牌地位及优势。
咨询